show episodes
 
Showcasing major breakthroughs in the field, Project Oncology® educates and assists the heroes who dedicate their lives to pioneering new advancements in the war against cancer. Hear from leading oncologists as they discuss essential screening and diagnostic tools, emerging therapies, counseling strategies, and more.
 
Loading …
show series
 
Host: Jacob Sands, MD Cancer care has evolved since the initial outbreak of the COVID-19 pandemic. What do we need to know about caring for our cancer patients during this winter season? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston shares what cancer patients can do to take care of themselves during the winter…
 
Guest: Mariana Chavez MacGregor, MD, MSC The healthcare disparity crisis in the breast cancer field has prevented the benefits of therapeutic advancements from being equally distributed throughout all populations. What can we do to overcome this obstacle? Dr. Mariana Chavez MacGregor, Associate Professor at the University of Texas MD Anderson Cance…
 
Host: Jacob Sands, MD Guest: Christopher Lathan, MD, MS, MPH Oftentimes, a patient’s zip code is a better indicator of health than blood pressure or genetics, highlighting a significant disparity among communities. How are barriers such as systemic racism contributing to this disparity, and what can we do to change that? Dr. Jacob Sands is joined b…
 
Guest: Christopher Lathan, MD, MS, MPH Healthcare professionals have found that zip code is a better indicator of health for many patients rather than cholesterol or genetics, highlighting a significant disparity in the field of medicine. What can we do to overcome this obstacle? Dr. Christopher Lathan, Associate Medical Director of the Dana Farber…
 
Host: Jacob Sands, MD Guest: Taofeek K. Owonikoko, MD, PhD, MSCR After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medica…
 
Host: Jacob Sands, MD Guest: Nabil F. Saba, MD Emerging research on head and neck cancer has moved away from HPV-negative diseases upon the discovery of HPV-positive diseases, specifically HPV-positive oropharynx cancer. What do we know about managing and treating this disease? Dr. Nabile Saba dives into treatment considerations, specifically immun…
 
Host: Jacob Sands, MD Guest: Nabil F. Saba, MD Since head and neck cancer is still to a large extent a surgical disease, the COVID-19 pandemic had an immediate impact on its management. Here to share how he pivoted his approach and how the pandemic might impact the future of head and neck cancer care is Dr. Nabil Saba, a Professor and Vice Chair fo…
 
Host: Edward Chu, MD Guest: Michael J. Overman, MD Recent immunotherapy approvals have changed the treatment paradigm for first and subsequent lines of treatment for patients with microsatellite-high or mismatch repair deficient metastatic colorectal cancer. Join us as we deep dive into recent and newly emergent data to better understand how to bri…
 
Host: Jennifer Caudle, DO Guest: Suma Satti, MD Small cell lung cancer is an aggressive form of lung cancer, and until recently therapeutic options have been limited. Joining Dr. Jennifer Caudle to discuss the role of immunotherapy in combination with chemotherapy in the treatment of this devastating disease as well as recent data from a clinical t…
 
Host: Jacob Sands, MD Guest: Therese T. Bevers, MD Fear of the COVID-19 pandemic has led to added safety precautions that have prevented patients from receiving much-needed cancer screenings. How will this impact the field of oncology, and what can we do to encourage patients to get their screenings? Dr. Therese Beavers, Medical Director of the Can…
 
Host: Paul P. Doghramji, MD, FAAFP Guest: Corey S. Cutler, MD, MPH, FRCPC Guest: Doris M. Ponce, MD Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, …
 
Host: Stephen Cohen, MD Guest: Thomas C. Wright, Jr., MD Regardless of the cervical cancer screening (CCS) approach used, effective triage tests are needed to improve diagnostic evaluation. An ideal screening and triage approach should identify as many precancerous lesions as possible while referring as few women as possible to colposcopy. Learn ho…
 
Host: Robert Mocharnuk, MD Guest: Richard S. Finn, MD Guest: Amit Singal, MD, MS The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinic…
 
Host: Scott Kopetz, MD, PhD Guest: Prof Eric Van Cutsem, MD, PhD Dr. Scott Kopetz and Prof. Eric Van Cutsem evaluate both the initial and updated pivotal outcomes from the BEACON trial in second- and third-line BRAF V600E-mutated metastatic colorectal cancer. They extend their discussion of these practice-changing results to include the early-stage…
 
Host: Scott Kopetz, MD, PhD Guest: Prof Eric Van Cutsem, MD, PhD Guest: Josep Tabernero, MD, PhD Dr. Scott Kopetz, Prof. Eric Van Cutsem, and Dr. Josep Tabernero engage in a panel discussion with a focus on the practice-changing initial and subsequently updated mature findings from the BEACON trial. These pivotal findings alter the standard of care…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login